Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo
Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination
Institute of Tropical Medicine, Belgium
300 participants
May 15, 2026
INTERVENTIONAL
Conditions
Summary
The study Mbote-TRAXX evaluates humoral and cellular immune responses in individuals vaccinated against mpox with the MVA-BN or LC16m8 vaccine administered as part of a routine mpox vaccination campaign in Kinshasa, Democratic Republic of the Congo (DRC). Participants will be followed up at multiple time points after vaccination in order to assess the kinetics and durability of the immune response by collection of blood samples. It is planned to include approximately 150 participants vaccinated with MVA-BN and 150 participants vaccinated with LC16m8.
Eligibility
Inclusion Criteria4
- Any person aged 18 years old or over at the time of giving informed consent, of any gender
- Participant received the MVA-BN or LC16m8 mpox vaccine as part of the national vaccination campaign
- Participant has the capacity and willingness to give informed written consent
- Participant agrees to adhere to the study's follow-up schedule
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
10 mL of blood will be collected at every visit and additional 20 mL blood samples will be taken from a subgroup of participants at every visit.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07499739